New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 5, 2014
16:23 EDTCYTXCytori Therapeutics places enrollment in ATHENA, ATHENA II trials on hold
Cytori Therapeutics has placed enrollment in the ATHENA and ATHENA II trials on clinical hold and therefore anticipates that it will not be possible to complete enrollment of the ATHENA I trial prior to the end of 2014 as previously anticipated. The decision to place the trials on hold was based on a safety review of reported cerebrovascular events. Symptoms occurred in three patients, of which two patients’ symptoms fully resolved within a short period of time and the third patient has had substantial resolution of symptoms. Such events had not been previously reported in Cytori’s other cardiovascular trials and appear to be related in part to the medical co-morbidities in the treated population and the complex nature of the procedures involved in the trial.
News For CYTX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 12, 2015
06:43 EDTCYTXCytori Therapeutics coverage assumed with a Buy at Ascendiant
Subscribe for More Information
May 11, 2015
16:29 EDTCYTXCytori Therapeutics reports Q1 EPS ex-charge (7c), consensus 7c
Reports Q1 revenue $902,000, consensus $2.44M. Reports cash and debt balances at March 31 of approximately $13.2M.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use